Promising drug may shrink inoperable tumors in kids with rare genetic condition
NCT ID NCT01362803
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 7 times
Summary
This study tests a drug called selumetinib in children and young adults (ages 3-18) with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be removed by surgery. The goal is to see if the drug can shrink or slow the growth of these tumors. Participants take the drug twice daily and are monitored for side effects and tumor changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMA, PLEXIFORM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Children's National Medical Center
Washington D.C., District of Columbia, 20010, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229-3039, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Light-Activated cream could slow growth of NF1 skin tumors
- Real-World study tracks Selumetinib's impact on NF1 tumors in children
- Could a cholesterol drug boost reading skills in kids with NF1?
- Antioxidant drug shows promise for kids with NF1
- New drug combo shows promise for rare nerve tumors
- Can a simple walk test spot motor trouble in kids with NF1?